These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 21233336)
1. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Barker HE; Chang J; Cox TR; Lang G; Bird D; Nicolau M; Evans HR; Gartland A; Erler JT Cancer Res; 2011 Mar; 71(5):1561-72. PubMed ID: 21233336 [TBL] [Abstract][Full Text] [Related]
2. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405 [TBL] [Abstract][Full Text] [Related]
3. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577 [TBL] [Abstract][Full Text] [Related]
4. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878 [TBL] [Abstract][Full Text] [Related]
5. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800 [TBL] [Abstract][Full Text] [Related]
6. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836 [TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498 [TBL] [Abstract][Full Text] [Related]
8. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer. Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417 [TBL] [Abstract][Full Text] [Related]
9. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Barker HE; Bird D; Lang G; Erler JT Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674 [TBL] [Abstract][Full Text] [Related]
11. LOXL2 in cancer: regulation, downstream effectors and novel roles. Wen B; Xu LY; Li EM Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981 [TBL] [Abstract][Full Text] [Related]
12. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348 [TBL] [Abstract][Full Text] [Related]
13. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718 [TBL] [Abstract][Full Text] [Related]
14. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism. Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200 [TBL] [Abstract][Full Text] [Related]
15. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025 [TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer. Cui X; Wang G; Shen W; Huang Z; He H; Cui L Oncol Rep; 2018 Aug; 40(2):932-942. PubMed ID: 29845296 [TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967 [TBL] [Abstract][Full Text] [Related]
18. A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer. Xia Q; Du Z; Chen M; Zhou X; Bai W; Zheng X; Lin L; Zhao Y; Ding J; Wu Z; Zou H; Wang S; Xu L; Li E; Wu B Mol Oncol; 2023 Nov; 17(11):2451-2471. PubMed ID: 37753805 [TBL] [Abstract][Full Text] [Related]
19. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway. Hong X; Yu JJ Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490 [TBL] [Abstract][Full Text] [Related]
20. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]